Suppr超能文献

人肝癌细胞和人单核细胞上丝氨酸蛋白酶抑制剂-酶复合物受体的鉴定。

Identification of a serpin-enzyme complex receptor on human hepatoma cells and human monocytes.

作者信息

Perlmutter D H, Glover G I, Rivetna M, Schasteen C S, Fallon R J

机构信息

Department of Pediatrics, Washington University School of Medicine, Saint Louis, MO 63110.

出版信息

Proc Natl Acad Sci U S A. 1990 May;87(10):3753-7. doi: 10.1073/pnas.87.10.3753.

Abstract

Formation of the covalently stabilized complex of alpha 1-antitrypsin (alpha 1-AT) with neutrophil elastase, the archetype of serine proteinase inhibitor serpin-enzyme complexes, is associated with structural rearrangement of the alpha 1-AT molecule and hydrolysis of a reactive-site peptide bond. An approximately 4-kDa carboxyl-terminal cleavage fragment is generated. alpha 1-AT-elastase complexes are biologically active, possessing chemotactic activity and mediating increases in expression of the alpha 1-AT gene in human monocytes and macrophages. This suggested that structural rearrangement of the alpha 1-AT molecule, during formation of a complex with elastase, exposes a domain that is recognized by a specific cell surface receptor or receptors. To test this hypothesis, the known three-dimensional structure of alpha 1-AT and comparisons of the primary structures of the serpins were used to select a potentially exteriorly exposed and highly conserved region in the complexed form of alpha 1-AT as a candidate ligand (carboxyl-terminal fragment, amino acids 359-374). We show here that synthetic peptides based on the sequence of this region bind specifically and saturably to human hepatoma cells and human monocytes (Kd = 4.0 X 10(-8) M, 4.5 X 10(5) plasma membrane receptors per cell) and mediate increases in synthesis of alpha 1-AT. Binding of peptide 105Y (Ser-Ile-Pro-Pro-Glu-Val-Lys-Phe-Asn-Lys-Pro-Phe-Val-Tyr-Leu-Ile) is blocked by alpha 1-AT-elastase complexes, antithrombin III (AT III)-thrombin complexes, alpha 1-antichymotrypsin (alpha 1-ACT)-cathepsin G complexes, and, to a lesser extent, complement component C1 inhibitor-C1s complexes, but not by the corresponding native proteins. Binding of peptide 105Y is also blocked by peptides with sequence corresponding to carboxy-terminal fragments of the serpins AT III and alpha 1-ACT, but not by peptides having the sequence of the extreme amino terminus of alpha 1-AT. The results also show that peptide 105Y inhibits binding of 125I-labeled alpha 1-AT-elastase complexes. Thus, these studies demonstrate an abundant, relatively high-affinity cell surface receptor which recognizes serpin-enzyme complexes (SEC receptor). This receptor is capable of modulating the production of at least one of the serpins, alpha 1-AT. Since the ligand specificity is similar to that previously described for in vivo clearance of serpin-enzyme complexes, the SEC receptor may also be involved in the clearance of certain serpin-enzyme complexes.

摘要

α1-抗胰蛋白酶(α1-AT)与中性粒细胞弹性蛋白酶形成的共价稳定复合物是丝氨酸蛋白酶抑制剂丝氨酸蛋白酶抑制因子-酶复合物的原型,它与α1-AT分子的结构重排及活性位点肽键的水解有关。会产生一个约4 kDa的羧基末端裂解片段。α1-AT-弹性蛋白酶复合物具有生物活性,拥有趋化活性,并能介导人类单核细胞和巨噬细胞中α1-AT基因表达的增加。这表明在与弹性蛋白酶形成复合物的过程中,α1-AT分子的结构重排暴露了一个能被特定细胞表面受体识别的结构域。为了验证这一假设,利用α1-AT已知的三维结构以及丝氨酸蛋白酶抑制因子的一级结构比较,在α1-AT的复合形式中选择一个潜在的外部暴露且高度保守的区域作为候选配体(羧基末端片段,氨基酸359 - 374)。我们在此表明,基于该区域序列的合成肽能特异性且饱和地结合人肝癌细胞和人单核细胞(解离常数Kd = 4.0×10⁻⁸ M,每个细胞有4.5×10⁵个质膜受体),并介导α1-AT合成的增加。肽105Y(Ser-Ile-Pro-Pro-Glu-Val-Lys-Phe-Asn-Lys-Pro-Phe-Val-Tyr-Leu-Ile)的结合被α1-AT-弹性蛋白酶复合物、抗凝血酶III(AT III)-凝血酶复合物、α1-抗糜蛋白酶(α1-ACT)-组织蛋白酶G复合物以及在较小程度上被补体成分C1抑制因子-C1s复合物阻断,但不被相应的天然蛋白质阻断。肽105Y的结合也被具有与丝氨酸蛋白酶抑制因子AT III和α1-ACT的羧基末端片段相对应序列的肽阻断,但不被具有α1-AT极端氨基末端序列的肽阻断。结果还表明,肽105Y抑制¹²⁵I标记的α1-AT-弹性蛋白酶复合物的结合。因此,这些研究证明了一种丰富的、亲和力相对较高的细胞表面受体,它能识别丝氨酸蛋白酶抑制因子-酶复合物(SEC受体)。该受体能够调节至少一种丝氨酸蛋白酶抑制因子α1-AT的产生。由于配体特异性与先前描述的丝氨酸蛋白酶抑制因子-酶复合物体内清除的特异性相似,SEC受体可能也参与某些丝氨酸蛋白酶抑制因子-酶复合物的清除。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9876/53981/93cbeb293824/pnas01035-0128-a.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验